TrialHub is the winner of DPHARM Idol Disrupt at the 15th annual DPHARM: Disruptive Innovations to Modernize Clinical Research 2025 event.
“By mapping the patient journey from diagnosis to treatment and answering the What, When, Where, Who, and How, we can finally design trials that fit how patients actually live and receive care.”
TrialHub, represented by Maya Zlatanova, CEO and Co-founder, brings research closer to patients by automating standard-of-care research across 70+ countries to help sponsors design patient-aligned protocols, optimize site selection, and accelerate recruitment while reducing costly amendments.
“With 80% of clinical trials delayed due to slow recruitment, it's clear the industry is designing trials for 'unicorn patients.' It's time we start adapting protocols to patients,” said Ms Zlatanova. “By mapping the patient journey from diagnosis to treatment and answering the What, When, Where, Who, and How, we can finally design trials that fit how patients actually live and receive care.”
TrialHub had six minutes to present how they are solving problems in clinical trials in front of a panel of judges representing R&D executives, patient advocates, and life science investors.
“Creating dynamic patient journeys and country-specific patient pathways helps us to ensure that trials are well-designed, we can avoid trial amendments, and meet patients where they are. TrialHub is bringing research closer to patients by helping to design trials that match the patient, and not the other way around,” said Siân Ratcliffe, PhD, SVP, Head of Quantitative Sciences & Development Operations, Biogen, and 2025 DPHARM Idol Disrupt judge.
TrialHub had strong competition from the other DPHARM Idol Disrupt contenders:
• Dandelion Health, represented by Elliott Green, Co-founder and CEO
• Grove AI, represented by Trân Lê, CEO and Co-founder
• IgniteData, represented by Richard Yeatman, COO and Co-founder
• OmniScience, represented by Angela Holmes, CEO and Co-founder
• Strategikon, represented by Andrei Antonescu, Head of Product
"Creating dynamic patient journeys and country-specific patient pathways helps us to ensure that trials are well-designed, we can avoid trial amendments, and meet patients where they are."
The DPHARM Idol Disrupt 2025 judges were:
• Mohammed Ali, R&D Head of Business Performance & Analytics, CMO Office, Astellas
• Esther Dyson, Author, “Term Limits”
• Rozanno Gonzales, MS, Clinical Innovation and Technology Leader, Genentech
• Bill Illis, Head, Technology and Collaboration, Novartis
• Hassan Kadhim, Head of Business Engagement, Clinical Operations and Clinical Development, Vertex Pharmaceuticals
• Julien Kroll, Strategic Lead, Digital Health and Real World Science, Bayer
• Sarah Krüg, Executive Director / CEO, Cancer101 / Health Collaboratory
• Yvonne McLean Florence, MDiv, Patient Advocate and 2023 Elevate Ambassador, National Coalition for Cancer Survivorship
• Siân Ratcliffe, PhD, SVP, Head of Quantitative Sciences & Development Operations, Biogen
• Doug Schantz, SVP, Clinical Operations, Asklepios BioPharmaceutical, Inc.
• Gina Schweizer, MS, MBA, Vice President, Head of Strategy, Operations and Analysis & Reporting, Genmab
• Mark Travers, PhD, MBA, Former VP, Head Global Clinical Trial Operations, Regions and Regional Operations, Merck & Co., Inc.
• Donna Usiskin, Chief Strategy Officer, New Enterprise Ventures
The moderator of judges was:
• Sean Lynch, Innovative Capabilities Head, Innovative Trial Operations, Novartis
The DPHARM Idol Disrupt 2025 moderators were:
• Valerie Bowling, Executive Director, Conference Forum
• Tracey Kimball, Senior Conference Producer, DPHARM
For more information on DPHARM, go to DPHARMconference.com.
